Aptahem today announced that the company is expanding its team with Suzanne Kilany as Clinical Research Director for the next step in the development of the company’s lead drug candidate, Apta-1. Suzanne will primarily lead and coordinate the planning...
Read MoreBioStock published an article on 2 April 2020 about Aptahem, which can be read in full below. Aptahem has recently published an abstract containing data on its lead drug candidate Apta-1, which is being developed as an emergency treatment for...
Read MoreAptahem should have attended the ISICEM conference in Brussels these days, but it has been postponed until September 2020. The abstract that the Aptahem team should have presented at the conference has however now been published in the Critical...
Read MoreBioStock published an article on 16 March 2020 about sepsis and covid-19, which can be read in full below. A new study published in The Lancet shows that sepsis was the most common complication in more than half of...
Read MoreAptahem had planned to participate in both BIO Europe Spring and ISICEM during March, but one has been cancelled and the other postponed for six months due to the risk of spreading the Corona virus. The meetings that Aptahem...
Read MoreBioStock published an article on 4 March 2020 about Aptahem, which can be read in full below. Aptahem has been listed as a member of the American MTEC, a consortium that cooperates with the U.S. Army Medical Research and...
Read MoreAptahem (publ) today announced that the company now enters a consortium together with Örebro University, the pharmaceutical development company AnaMar and Dalhousie University in Canada. The newly established consortium aims to evaluate new strategies to reduce inflammation, thrombosis and...
Read MoreAptahem (publ) today announce positive final results from the exploratory sepsis study with non human primates, the NHP study. The new preclinical results continue to support Apta-1’s multifunctional drug candidate potential within the treatment of sepsis. The completed comprehensive...
Read MoreAptahem (publ) announced today that a presentation entitled “Apta-1, a novel RNA aptamer, improves outcome in an animal model of sepsis” will be held at the World Congress of Intensive Care in Melbourne, Australia, October 14-18, 2019. This conference...
Read MoreAptahem (publ) announced today that the company has signed an agreement with a GMP-certified (Good Manufacturing Practice) contract manufacturer, LGC Group. LGC Group will manufacture the company’s lead candidate, Apta-1, for the concluding toxicological studies and the production is...
Read More